Selection of active ScFv to G-protein-coupled receptor CCR5 using surface antigen-mimicking peptides.

This study describes the use of cyclic peptides for use in the selection of single-chain (ScFv) antibodies specific for the HIV-1 coreceptor CCR5, a representative G-protein-coupled receptor (GPCR). A tandem ligation strategy was developed for preparing biotinylated cyclic peptides, first through an orthogonal end-to-end ligation and then a chemoselective ligation with functionalized biotin. Cyclic peptides mimicking the extracellular loops of CCR5 and their unconstrained counterparts were then used for solution-phase selection of ScFv antibodies from a phage display antibody library. Antibodies reactive with CCR5 on cells were detected using a homogeneous high throughput assay. Of 19 isolated ScFv antibodies that bound to CCR5+ cells, three inhibited CCR5-mediated but not CXCR4-mediated HIV infection. Only ScFvs selected by binding to cyclic constrained peptides exhibited inhibitory activity. Our results demonstrate that surface-antigen mimetics of a GPCR are effective tools for selecting active, site-specific ScFv antibodies that hold promise as immunological reagents and therapeutics.

[1]  T. Kenakin,et al.  Recent Progress in Discovery of Small‐Molecule CCR5 Chemokine Receptor Ligands as HIV‐1 Inhibitors , 2003 .

[2]  Thomas P. Sakmar,et al.  Analysis of the Mechanism by Which the Small-Molecule CCR5 Antagonists SCH-351125 and SCH-350581 Inhibit Human Immunodeficiency Virus Type 1 Entry , 2003, Journal of Virology.

[3]  Marc Parmentier,et al.  Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. , 2002, Molecular biology of the cell.

[4]  S. Kaveri,et al.  Antibodies to C-C Chemokine Receptor 5 in Normal Human IgG Block Infection of Macrophages and Lymphocytes with Primary R5-Tropic Strains of HIV-11 , 2001, The Journal of Immunology.

[5]  T. Whittall,et al.  Immunogenicity of the Extracellular Domains of C-C Chemokine Receptor 5 and the In Vitro Effects on Simian Immunodeficiency Virus or HIV Infectivity1 , 2001, The Journal of Immunology.

[6]  A. Trkola,et al.  Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140 , 2001, Journal of Virology.

[7]  J. Tam,et al.  Methods and strategies of peptide ligation. , 2002, Biopolymers.

[8]  B. Zuber,et al.  Induction of immune responses and break of tolerance by DNA against the HIV-1 coreceptor CCR5 but no protection from SIVsm challenge. , 2000, Virology.

[9]  C. Barbas,et al.  Generation and Characterization of a Recombinant Human CCR5-specific Antibody , 2000, The Journal of Biological Chemistry.

[10]  S W Lin,et al.  Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[11]  L. Lopalco,et al.  CCR5-Reactive Antibodies in Seronegative Partners of HIV-Seropositive Individuals Down-Modulate Surface CCR5 In Vivo and Neutralize the Infectivity of R5 Strains of HIV-1 In Vitro1 , 2000, The Journal of Immunology.

[12]  J. Sodroski,et al.  Enhanced Expression, Native Purification, and Characterization of CCR5, a Principal HIV-1 Coreceptor* , 1999, The Journal of Biological Chemistry.

[13]  Yufei Wang,et al.  Allo-immunization elicits CD8+ T cell-derived chemokines, HIV suppressor factors and resistance to HIV infection in women , 1999, Nature Medicine.

[14]  Yufei Wang,et al.  Induction of inhibitory antibodies to the CCR5 chemokine receptor and their complementary role in preventing SIV infection in macaques , 1999, European journal of immunology.

[15]  Q. Sattentau,et al.  Constitutive cell surface association between CD4 and CCR5. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[16]  William C. Olson,et al.  Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, gp120 Binding, and CC-Chemokine Activity by Monoclonal Antibodies to CCR5 , 1999, Journal of Virology.

[17]  H. Guy,et al.  Epitope Mapping of CCR5 Reveals Multiple Conformational States and Distinct but Overlapping Structures Involved in Chemokine and Coreceptor Function* , 1999, The Journal of Biological Chemistry.

[18]  D. Lowy,et al.  Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Tam,et al.  Orthogonal ligation strategies for peptide and protein. , 1999, Biopolymers.

[20]  J. Tam,et al.  Controlled lipidation and encapsulation of peptides as a useful approach to mucosal immunizations. , 1998, Journal of immunology.

[21]  M. Parmentier,et al.  Directed selection of MIP-1α neutralizing CCR5 antibodies from a phage display human antibody library , 1998, Nature Biotechnology.

[22]  R. Koup,et al.  The HIV type 1 coreceptor CCR5 and its role in viral transmission and disease progression. , 1998, AIDS research and human retroviruses.

[23]  J. Sodroski,et al.  A Tyrosine-Rich Region in the N Terminus of CCR5 Is Important for Human Immunodeficiency Virus Type 1 Entry and Mediates an Association between gp120 and CCR5 , 1998, Journal of Virology.

[24]  Luc Montagnier,et al.  HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene , 1998, The Lancet.

[25]  Kuan-Teh Jeang,et al.  Mechanism of Transdominant Inhibition of CCR5-mediated HIV-1 Infection by ccr5Δ32* , 1997, The Journal of Biological Chemistry.

[26]  Marc Parmentier,et al.  The Second Extracellular Loop of CCR5 Is the Major Determinant of Ligand Specificity* , 1997, The Journal of Biological Chemistry.

[27]  J. Allen,et al.  Antibody engineering — A practical approach: edited by John McCafferty, Hennie R. Hoogenboom and Davide J. Chiswell, IRL Press, 1996. £55.00 (xxiii + 325 pages) ISBN 0 19 963593 5 , 1997 .

[28]  A. Trkola,et al.  Co-receptors for HIV-1 entry. , 1997, Current opinion in immunology.

[29]  Nancy Sullivan,et al.  CCR5 Levels and Expression Pattern Correlate with Infectability by Macrophage-tropic HIV-1, In Vitro , 1997, The Journal of experimental medicine.

[30]  James P. Tam,et al.  Synthesis and Application of Unprotected Cyclic Peptides as Building Blocks for Peptide Dendrimers , 1997 .

[31]  R. Connor,et al.  Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.

[32]  Steven M. Wolinsky,et al.  The role of a mutant CCR5 allele in HIV–1 transmission and disease progression , 1996, Nature Medicine.

[33]  Richard A Koup,et al.  Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.

[34]  Stephen C. Peiper,et al.  Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.

[35]  J. Moore,et al.  The beta-chemokines, HIV type 1 second receptors, and exposed uninfected persons. , 1996, AIDS research and human retroviruses.

[36]  M. Reitz,et al.  Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1 , 1995, Journal of virology.

[37]  D. Ho,et al.  Macromolecular assemblage in the design of a synthetic AIDS vaccine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[38]  M. Emerman,et al.  Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene , 1992, Journal of virology.

[39]  J. Tam,et al.  Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[40]  G. Prota,et al.  On the reaction of ninhydrin with cysteine and its analogues:: A revision , 1973 .